Your browser doesn't support javascript.
loading
Development and implementation of guidelines for the management of depression: a systematic review.
Lee, Yena; Brietzke, Elisa; Cao, Bing; Chen, Yan; Linnaranta, Outi; Mansur, Rodrigo B; Cortes, Paulina; Kösters, Markus; Majeed, Amna; Tamura, Jocelyn K; Lui, Leanna M W; Vinberg, Maj; Keinänen, Jaakko; Kisely, Steve; Naveed, Sadiq; Barbui, Corrado; Parker, Gary; Owolabi, Mayowa; Nishi, Daisuke; Lee, JungGoo; Srisurapanont, Manit; Gill, Hartej; Guo, Lan; Balanzá-Martínez, Vicent; Partonen, Timo; Nolen, Willem A; Lee, Jae-Hon; Kim, Ji Hwan; Chavannes, Niels H; Ewais, Tatjana; Atienza-Carbonell, Beatriz; Silven, Anna V; Yasuma, Naonori; Gil, Artyom; Novikov, Andrey; Lacey, Cameron; Versluis, Anke; von Malortie, Sofia; Chan, Lai Fong; Waqas, Ahmed; Purgato, Marianna; Aardoom, Jiska Joëlle; Ly-Uson, Josefina T; Sim, Kang; Tuineag, Maria; van der Kleij, Rianne M J J; van Luenen, Sanne; Suttajit, Sirijit; Hajek, Tomas; Lee, Yu Wei.
Afiliação
  • Lee Y; Mood Disorders Psychopharmacology Unit, Toronto Western Hospital, University Health Network, 399 Bathurst St 9MP-325, Toronto, Ontario, Canada.
  • Brietzke E; Department of Psychiatry, Queen's University School of Medicine, Kingston, Canada.
  • Cao B; School of Psychology and Key Laboratory of Cognition and Personality, Southwest University, Chongqing, China.
  • Chen Y; Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.
  • Linnaranta O; Bipolar Disorders Clinic, Douglas Mental Health University Institute, Montréal, Canada.
  • Mansur RB; Mood Disorders Psychopharmacology Unit, Toronto Western Hospital, University Health Network, 399 Bathurst St 9MP-325, Toronto, Ontario, Canada.
  • Cortes P; Pontificia Universidad Católica de Chile, Santiago, Región Metropolitana, Chile.
  • Kösters M; Department of Psychiatry II, Ulm University, Ulm, Germany.
  • Majeed A; Mood Disorders Psychopharmacology Unit, Toronto Western Hospital, University Health Network, 399 Bathurst St 9MP-325, Toronto, Ontario, Canada.
  • Tamura JK; Mood Disorders Psychopharmacology Unit, Toronto Western Hospital, University Health Network, 399 Bathurst St 9MP-325, Toronto, Ontario, Canada.
  • Lui LMW; Mood Disorders Psychopharmacology Unit, Toronto Western Hospital, University Health Network, 399 Bathurst St 9MP-325, Toronto, Ontario, Canada.
  • Vinberg M; Psychiatric Research Unit, Psychiatric Centre North Zealand, Hilleroed, University Hospital of Copenhagen, Copenhagen, Denmark.
  • Keinänen J; Department of Public Health Solutions, National Institute for Health and Welfare, Helsinki, Finland.
  • Kisely S; School of Clinical Medicine, The University of Queensland, Brisbane, Australia.
  • Naveed S; Department of Psychiatry and Behavioral Sciences, University of Kansas Medical Center, Kansas, USA.
  • Barbui C; WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, Department of Biomedicine and Movement Sciences, Verona, Italy.
  • Parker G; Global Alliance for Chronic Diseases, Wellcome Trust, London, England.
  • Owolabi M; Center for Genomics and Precision Medicine, University of Ibadan, Ibadan, Nigeria.
  • Nishi D; Department of Mental Health, The University of Tokyo, Tokyo, Japan.
  • Lee J; Paik Institute for Clinical Research, Inje University, Busan, Republic of Korea.
  • Srisurapanont M; Department of Psychiatry, Chiang Mai University, Chiang Mai, Thailand.
  • Gill H; Mood Disorders Psychopharmacology Unit, Toronto Western Hospital, University Health Network, 399 Bathurst St 9MP-325, Toronto, Ontario, Canada.
  • Guo L; School of Public Health, Sun Yat-sen University, Guangdong, China.
  • Balanzá-Martínez V; Teaching Unit of Psychiatry and Psychological Medicine, University of Valencia, Valencia, CIBERSAM, Spain.
  • Partonen T; Department of Public Health Solutions, National Institute for Health and Welfare, Helsinki, Finland.
  • Nolen WA; Department of Psychiatry, University of Groningen, Groningen, Netherlands.
  • Lee JH; Department of Psychiatry, Gyeongsang National University Hospital, Jinju, Republic of Korea.
  • Kim JH; Paik Institute for Clinical Research, Inje University, Busan, Republic of Korea.
  • Chavannes NH; Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands.
  • Ewais T; School of Clinical Medicine, The University of Queensland, Brisbane, Australia.
  • Atienza-Carbonell B; Medical School, University of Valencia, Valencia, Spain.
  • Silven AV; Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands.
  • Yasuma N; Department of Mental Health, The University of Tokyo, Tokyo, Japan.
  • Gil A; WHO European Office for the Prevention and Control of Noncommunicable Diseases, Division of Country Health Programme, Moscow, Russian Federation.
  • Novikov A; Psychiatric and Neurological Hospital, Surgut, Russian Federation.
  • Lacey C; Maori Indigenous Health Institute, University of Otago, Christchurch, New Zealand.
  • Versluis A; Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands.
  • von Malortie S; The National Board of Health and Welfare, Stockholm, Sweden.
  • Chan LF; Mood Disorders Psychopharmacology Unit, Toronto Western Hospital, University Health Network, 399 Bathurst St 9MP-325, Toronto, Ontario, Canada.
  • Waqas A; Department of Psychiatry, Queen's University School of Medicine, Kingston, Canada.
  • Purgato M; Mood Disorders Psychopharmacology Unit, Toronto Western Hospital, University Health Network, 399 Bathurst St 9MP-325, Toronto, Ontario, Canada.
  • Aardoom JJ; School of Psychology and Key Laboratory of Cognition and Personality, Southwest University, Chongqing, China.
  • Ly-Uson JT; WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, Department of Biomedicine and Movement Sciences, Verona, Italy.
  • Sim K; Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands.
  • Tuineag M; Mood Disorders Psychopharmacology Unit, Toronto Western Hospital, University Health Network, 399 Bathurst St 9MP-325, Toronto, Ontario, Canada.
  • van der Kleij RMJJ; Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.
  • van Luenen S; Mood Disorders Psychopharmacology Unit, Toronto Western Hospital, University Health Network, 399 Bathurst St 9MP-325, Toronto, Ontario, Canada.
  • Suttajit S; Bipolar Disorders Clinic, Douglas Mental Health University Institute, Montréal, Canada.
  • Hajek T; Mood Disorders Psychopharmacology Unit, Toronto Western Hospital, University Health Network, 399 Bathurst St 9MP-325, Toronto, Ontario, Canada.
  • Lee YW; Pontificia Universidad Católica de Chile, Santiago, Región Metropolitana, Chile.
Bull World Health Organ ; 98(10): 683-697H, 2020 Oct 01.
Article em En | MEDLINE | ID: mdl-33177758
ABSTRACT

OBJECTIVE:

To evaluate the development and implementation of clinical practice guidelines for the management of depression globally.

METHODS:

We conducted a systematic review of existing guidelines for the management of depression in adults with major depressive or bipolar disorder. For each identified guideline, we assessed compliance with measures of guideline development quality (such as transparency in guideline development processes and funding, multidisciplinary author group composition, systematic review of comparative efficacy research) and implementation (such as quality indicators). We compared guidelines from low- and middle-income countries with those from high-income countries.

FINDINGS:

We identified 82 national and 13 international clinical practice guidelines from 83 countries in 27 languages. Guideline development processes and funding sources were explicitly specified in a smaller proportion of guidelines from low- and middle-income countries (8/29; 28%) relative to high-income countries (35/58; 60%). Fewer guidelines (2/29; 7%) from low- and middle-income countries, relative to high-income countries (22/58; 38%), were authored by a multidisciplinary development group. A systematic review of comparative effectiveness was conducted in 31% (9/29) of low- and middle-income country guidelines versus 71% (41/58) of high-income country guidelines. Only 10% (3/29) of low- and middle-income country and 19% (11/58) of high-income country guidelines described plans to assess quality indicators or recommendation adherence.

CONCLUSION:

Globally, guideline implementation is inadequately planned, reported and measured. Narrowing disparities in the development and implementation of guidelines in low- and middle-income countries is a priority. Future guidelines should present strategies to implement recommendations and measure feasibility, cost-effectiveness and impact on health outcomes.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Depressão / Transtorno Depressivo Maior Tipo de estudo: Guideline / Prognostic_studies / Systematic_reviews Limite: Adult / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Depressão / Transtorno Depressivo Maior Tipo de estudo: Guideline / Prognostic_studies / Systematic_reviews Limite: Adult / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article